The UK Microbiome Diagnostics Market was valued at $7.7 Million in 2023 and projected to reach to $15.7 Million by 2028, representing a compound annual growth rate of CAGR 15.3%. The UK microbiome diagnostics market is positioned for sustained expansion as healthcare providers recognize the clinical value of microbiome profiling in disease diagnosis and prevention.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
The UK microbiome diagnostics market reached $7.7 million in 2023 and is forecast to grow to $15.7 million by 2028, driven by a robust 15.3% CAGR, outpacing many other diagnostic segments in the British healthcare sector.
Rising investment in diagnostic infrastructure across the National Health Service is accelerating adoption of microbiome testing, with NHS trusts increasingly integrating these diagnostics into precision medicine protocols and personalized treatment pathways.
UK healthcare providers are rapidly embracing precision medicine approaches, with microbiome diagnostics becoming integral to understanding individual patient profiles and tailoring therapeutic interventions for improved clinical outcomes.
Growing public and clinical awareness of the gut microbiome's role in disease prevention, immune function, and metabolic health is driving demand for diagnostic testing across UK hospitals, private clinics, and wellness centers.
| Report Metric | Details |
|---|---|
| Base Year | 2023 |
| Fastest Growing Segment | SHOTGUN METAGENOMICS (Technology) |
| Forecast Period | 2023-2028 |
| Growth Rate | CAGR of 15.5% from 2023 to 2028 |
| Largest Segment | DISEASE DIAGNOSTIC APPLICATIONS (Application) |
| Market Size Base Year (Billions) | ~USD 0.15 (2023) |
| Revenue Forecast (Billions) | ~USD 0.3 (2028) |
| Segments Covered | Product, Technology, Sample, Application, Type, End User |
6 segment dimensions are covered across the global market.
| Segment | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | CAGR (%) |
|---|---|---|---|---|---|---|---|---|---|
| HOSPITALS | 3.8 | 4.4 | 5.1 | 5.8 | 6.7 | 7.7 | 8.8 | 10.2 | 14.9 |
| PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES | 0.4 | 0.5 | 0.5 | 0.6 | 0.7 | 0.8 | 0.9 | 1 | 14.9 |
| RESEARCH INSTITUTES | 1.6 | 1.8 | 2.1 | 2.4 | 2.8 | 3.3 | 3.9 | 4.5 | 16.5 |
| TOTAL | 5.8 | 6.7 | 7.7 | 8.8 | 10.2 | 11.8 | 13.6 | 15.7 | 15.3 |
The UK microbiome diagnostics market was valued at $7.7 million in 2023 and is expected to reach $15.7 million by 2028.
The UK microbiome diagnostics market is growing at a compound annual growth rate (CAGR) of 15.3% from 2023 to 2028.
Key drivers include NHS investment in precision medicine, increasing clinical evidence for microbiome testing, growing patient awareness of gut health, and expanding reimbursement pathways across the UK.
The UK market is experiencing strong demand from gastroenterology, immunology, metabolic disease, and infectious disease diagnostic applications.
The UK represents a significant portion of the European microbiome diagnostics market, supported by advanced healthcare infrastructure, regulatory clarity, and strong research capabilities.
The objective of the study is to analyze the key market dynamics such as drivers, opportunities, challenges, restraints, and key player strategies. To track companies’ developments such as product launches and approvals, expansions, and partnerships of the leading players, the competitive landscape of the microbiome diagnostic market to analyze market players on various parameters within the broad categories of business and product strategy. Top-down and bottom-up approaches were used to estimate the market size. To estimate the market size of segments and subsegments, the market breakdown and data triangulation were used.
The four steps involved in estimating the market size are
The secondary research data collection process involves the usage of secondary sources, directories, databases (such as Bloomberg Businessweek, Factiva, and D&B), annual reports, investor presentations, and SEC filings of companies. Secondary research was used to identify and collect information useful for the extensive, technical, market-oriented, and commercial study of the microbiome-based diagnostics market. A database of the key industry leaders was also prepared using secondary research.
The primary research data was collected after acquiring knowledge about the microbiome diagnostics market scenario through secondary research. A significant number of primary interviews were conducted with stakeholders from both the demand side (such as doctors, nurses, and hospital purchase managers) and supply side (such as included various industry experts, such as Directors, Chief X Officers (CXOs), Vice Presidents (VPs) from business development, marketing and product development teams, product manufacturers, wholesalers, channel partners, and distributors) across major countries of North America, Europe, Asia Pacific, Rest of the World. Approximately 40% of the primary interviews were conducted with stakeholders from the demand side while those from the supply side accounted for the remaining 60%. Primary data for this report was collected through questionnaires, emails, and telephonic interviews.
A breakdown of the primary respondents is provided below:

Note 1: Others include sales managers, marketing managers, and product managers.
Note 2: Tiers are defined based on a company’s total revenue. As of 2022: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 <USD 500 million.
To know about the assumptions considered for the study, download the pdf brochure
|
COMPANY NAME |
DESIGNATION |
|
DNA Genotek (US) |
Manager |
|
Viome Life Sciences (US) |
VP Sales |
|
Genetic Analysis AS (Norway) |
Regional Sales Head |
|
Becton, Dickinson and Company (US) |
Sales Director |
All major product manufacturers offering various microbiome diagnostics were identified at the global/regional level. Revenue mapping was done for the major players and was extrapolated to arrive at the global market value of each type of segment. The market value microbiome-based diagnostics market was also split into various segments and subsegments at the region and country level based on:

To know about the assumptions considered for the study, Request for Free Sample Report

After arriving at the overall market size—using the market size estimation processes—the market was split into several segments and subsegments. To complete the overall market engineering process and arrive at the exact statistics of each market segment and subsegment, the data triangulation, and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides in the microbiome-based diagnostics industry.
Microbiom diagnostic products are used to investigate and understand the complex communities of microorganisms living in and on the human body. Microbiome diagnostics involves collecting samples from various body sites, such as the skin, gut, mouth, and other mucosal surfaces, and analyzing the genetic material such as DNA, RNA of the microorganisms within these samples.
With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:
Full forecast, segment splits, and company analysis for all Microbiome Diagnostics Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report